Monte Rosa Therapeutics, Inc. (GLUE) stock
GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07+0.00 (0.00%)
Close on Nov 18, 2026Market cap $773.79MP/E –Yield –
Monte Rosa Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Monte Rosa Therapeutics's pe ratio was 82.1× on Jan 30, 2026.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jan 30, 2026 | 82.1× | +19.4 |
| 2025 | Dec 31, 2025 | 62.7× | – |
See a number that looks wrong?